Table 1.
Baseline characteristics and follow-up information of the corticosteroid user group and corticosteroid nonuser group
| Baseline characteristic | Corticosteroid users (n = 369, 35.7%) |
Corticosteroid nonusers (n = 665, 64.3%) |
P value |
|---|---|---|---|
| Male (n [%])/female (n) | 203 (55.0)/166 | 317 (47.7)/348 | 0.024 |
| Age (yr) | 34 ± 13 | 35 ± 11 | 0.082 |
| Systolic BP (mm Hg) | 125 ± 16 | 122 ± 16 | 0.006 |
| Diastolic BP (mm Hg) | 80 ± 12 | 78 ± 12 | 0.019 |
| Serum creatinine (mmol/l) | 106 (80–146) | 87 (70–114) | <0.001 |
| Proteinuria (g/24 h) | 3.0 (1.7–5.2) | 1.1 (0.6–1.9) | <0.001 |
| eGFR (ml/min per 1.73 m2) | 73 ± 33 | 86 ± 29 | <0.001 |
| Uric acid (μmol/l) | 387 ± 102 | 361 ± 101 | <0.001 |
| Hemoglobin (g/l) | 133 ± 20 | 134 ± 18 | 0.289 |
| Albumin (g/l) | 34 ± 8 | 39 ± 5 | <0.001 |
| Triglyceride (mmol/l) | 2.2 ± 1.6 | 1.9 ± 1.6 | 0.005 |
| Total cholesterol (mmol/l) | 5.9 ± 2.1 | 4.7 ± 1.1 | <0.001 |
| Follow-up (mo) | 49 (25–84) | 49 (28–85) | 0.615 |
| ESRD and death | 55 (14.9) | 51 (7.7) | <0.001 |
| SAEs | 46 (12.5) | 18 (2.7) | <0.001 |
| CKD stage | |||
| 1 | 116 (26.5) | 321 (73.5) | <0.001 |
| 2 | 108 (34.4) | 206 (65.6) | |
| 3 | 116 (48.3) | 124 (51.7) | |
| 4/5 | 29 (67.4) | 14 (32.6) |
Unless otherwise indicated values are n (%), means ± SDs, or median (25th–75th centiles). Bold values are statistically significant.
BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; SAEs, severe adverse effects.